{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:27:18Z","timestamp":1773415638238,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04628-7","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:33:57Z","timestamp":1770672837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MBD3 increased expression by BRD4 and facilitated castration-resistant prostate cancer cell proliferation by inhibiting PTEN"],"prefix":"10.1007","volume":"17","author":[{"given":"Liangming","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"1","key":"4628_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4628_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12672-022-00508-y","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Ma J, Xu C, Wang L, Yao Y, Wang X, Zi T, Bian C, Wu D, Wu G. Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis. Discov Oncol. 2022;13(1):54.","journal-title":"Discov Oncol"},{"issue":"6","key":"4628_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/cncr.23304","volume":"112","author":"RW Ross","year":"2008","unstructured":"Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112(6):1247\u201353.","journal-title":"Cancer"},{"issue":"2","key":"4628_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/cncr.31846","volume":"125","author":"SJ Curry","year":"2019","unstructured":"Curry SJ, Krist AH, Owens DK. Annual report to the Nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2019;125(2):317\u20138.","journal-title":"Cancer"},{"issue":"2","key":"4628_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467\u201379.","journal-title":"Eur Urol"},{"key":"4628_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3389\/fgene.2014.00428","volume":"5","author":"R Menafra","year":"2014","unstructured":"Menafra R, Stunnenberg HG. MBD2 and MBD3: elusive functions and mechanisms. Front Genet. 2014;5:428.","journal-title":"Front Genet"},{"issue":"3","key":"4628_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1242\/dev.083105","volume":"140","author":"N Reynolds","year":"2013","unstructured":"Reynolds N, O\u2019Shaughnessy A, Hendrich B. Transcriptional repressors: multifaceted regulators of gene expression. Development. 2013;140(3):505\u201312.","journal-title":"Development"},{"issue":"12","key":"4628_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/bies.10008","volume":"23","author":"PA Wade","year":"2001","unstructured":"Wade PA. Methyl CpG-binding proteins and transcriptional repression. BioEssays. 2001;23(12):1131\u20137.","journal-title":"BioEssays"},{"issue":"4","key":"4628_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-022-01831-5","volume":"127","author":"W Yan","year":"2022","unstructured":"Yan W, Han Q, Gong L, Zhan X, Li W, Guo Z, Zhao J, Li T, Bai Z, Wu J, et al. MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2. Br J Cancer. 2022;127(4):612\u201323.","journal-title":"Br J Cancer"},{"issue":"1","key":"4628_CR10","doi-asserted-by":"publisher","first-page":"112091","DOI":"10.1016\/j.yexcr.2020.112091","volume":"393","author":"H Wang","year":"2020","unstructured":"Wang H, Feng W, Chen W, He J, Min J, Liu Y, Li F, Chen J, Wu S, Chen B, et al. Methyl-CpG-binding domain 3 inhibits stemness of pancreatic cancer cells via Hippo signaling. Exp Cell Res. 2020;393(1):112091.","journal-title":"Exp Cell Res"},{"issue":"5","key":"4628_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5582\/bst.2020.01048","volume":"14","author":"T Ishibashi","year":"2020","unstructured":"Ishibashi T, Kajihara I, Mizuhashi S, Kuriyama H, Kimura T, Kanemaru H, Makino K, Miyashita A, Aoi J, Makino T, et al. Methyl-CpG binding domain protein 3: a new diagnostic marker and potential therapeutic target of melanoma. Biosci Trends. 2020;14(5):390\u20135.","journal-title":"Biosci Trends"},{"issue":"4","key":"4628_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0006-291X(03)00253-5","volume":"302","author":"SK Patra","year":"2003","unstructured":"Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun. 2003;302(4):759\u201366.","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"4628_CR13","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1158\/0008-5472.CAN-16-0559","volume":"76","author":"G Andrieu","year":"2016","unstructured":"Andrieu G, Tran AH, Strissel KJ, Denis GV. BRD4 regulates breast cancer dissemination through Jagged1\/Notch1 signaling. Cancer Res. 2016;76(22):6555\u201367.","journal-title":"Cancer Res"},{"issue":"7504","key":"4628_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278\u201382.","journal-title":"Nature"},{"issue":"7570","key":"4628_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538\u201342.","journal-title":"Nature"},{"issue":"7327","key":"4628_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective Inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"6","key":"4628_CR17","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain Inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell"},{"issue":"9","key":"4628_CR18","first-page":"4003","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, Li H, Xu C, Wang X, Wu G, Li C, Wu D. CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression. Am J Cancer Res. 2023;13(9):4003\u201320.","journal-title":"Am J Cancer Res"},{"issue":"26","key":"4628_CR19","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016;113(26):7124\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4628_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s40001-025-03371-z","volume":"30","author":"P Zhang","year":"2025","unstructured":"Zhang P, Liu Y, Pan L, Ma J, Chen X, Wu Y. KDM3B suppresses castration-resistance prostate cancer cell proliferation by promoting PTEN expression. Eur J Med Res. 2025;30(1):1090.","journal-title":"Eur J Med Res"},{"issue":"7","key":"4628_CR21","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1002\/ctm2.495","volume":"11","author":"Z Hong","year":"2021","unstructured":"Hong Z, Xiang Z, Zhang P, Wu Q, Xu C, Wang X, Shi G, Hong Z, Wu D. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. Clin Transl Med. 2021;11(7):e495.","journal-title":"Clin Transl Med"},{"issue":"4","key":"4628_CR22","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1021\/acsabm.0c01625","volume":"4","author":"J Lee","year":"2021","unstructured":"Lee J, Kwon Y, Jung J, Shin H, Park J. Immunostaining extracellular vesicles based on an aqueous Two-Phase system: for analysis of tetraspanins. ACS Appl Bio Mater. 2021;4(4):3294\u2013303.","journal-title":"ACS Appl Bio Mater"},{"issue":"5","key":"4628_CR23","doi-asserted-by":"publisher","first-page":"e96801","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A. IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9(5):e96801.","journal-title":"PLoS ONE"},{"issue":"4","key":"4628_CR24","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1530\/ERC-12-0285","volume":"20","author":"X Wu","year":"2013","unstructured":"Wu X, Gong S, Roy-Burman P, Lee P, Culig Z. Current mouse and cell models in prostate cancer research. Endocr Relat Cancer. 2013;20(4):R155\u2013170.","journal-title":"Endocr Relat Cancer"},{"issue":"36","key":"4628_CR25","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1038\/onc.2011.566","volume":"31","author":"ME Rusiniak","year":"2012","unstructured":"Rusiniak ME, Kunnev D, Freeland A, Cady GK, Pruitt SC. Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma. Oncogene. 2012;31(36):4034\u201344.","journal-title":"Oncogene"},{"issue":"6","key":"4628_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nsmb.3228","volume":"23","author":"BN Devaiah","year":"2016","unstructured":"Devaiah BN, Case-Borden C, Gegonne A, Hsu CH, Chen Q, Meerzaman D, Dey A, Ozato K, Singer DS. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. Nat Struct Mol Biol. 2016;23(6):540\u20138.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"4628_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1541-7786.MCR-15-0472","volume":"14","author":"IA Asangani","year":"2016","unstructured":"Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, et al. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res. 2016;14(4):324\u201331.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"4628_CR28","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ctrv.2015.05.003","volume":"41","author":"M Katsogiannou","year":"2015","unstructured":"Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev. 2015;41(7):588\u201397.","journal-title":"Cancer Treat Rev"},{"issue":"7406","key":"4628_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239\u201343.","journal-title":"Nature"},{"issue":"3","key":"4628_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4103\/aja.aja_19_19","volume":"21","author":"G Gritsina","year":"2019","unstructured":"Gritsina G, Gao WQ, Yu J. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. Asian J Androl. 2019;21(3):215\u201323.","journal-title":"Asian J Androl"},{"issue":"21","key":"4628_CR31","doi-asserted-by":"publisher","first-page":"6112","DOI":"10.1111\/febs.15804","volume":"288","author":"H Ashe","year":"2021","unstructured":"Ashe H, Krakowiak P, Hasterok S, Sleppy R, Roller DG, Gioeli D. Role of the runt-related transcription factor (RUNX) family in prostate cancer. FEBS J. 2021;288(21):6112\u201326.","journal-title":"FEBS J"},{"issue":"5308","key":"4628_CR32","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943\u20137.","journal-title":"Science"},{"issue":"1","key":"4628_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","volume":"95","author":"V Stambolic","year":"1998","unstructured":"Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95(1):29\u201339.","journal-title":"Cell"},{"issue":"2","key":"4628_CR34","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1096\/fj.201900677R","volume":"34","author":"MG Strainic","year":"2020","unstructured":"Strainic MG, Pohlmann E, Valley CC, Sammeta A, Hussain W, Lidke DS, Medof ME. RTK signaling requires C3ar1\/C5ar1 and IL-6R joint signaling to repress dominant PTEN, SOCS1\/3 and PHLPP restraint. FASEB J. 2020;34(2):2105\u201325.","journal-title":"FASEB J"},{"issue":"3","key":"4628_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/CS20160026","volume":"131","author":"HM Wise","year":"2017","unstructured":"Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 2017;131(3):197\u2013210.","journal-title":"Clin Sci (Lond)"},{"key":"4628_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.09.010","volume":"498","author":"K Nikhil","year":"2021","unstructured":"Nikhil K, Kamra M, Raza A, Shah K. Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo. Cancer Lett. 2021;498:1\u201318.","journal-title":"Cancer Lett"},{"key":"4628_CR37","doi-asserted-by":"publisher","first-page":"108793","DOI":"10.1016\/j.biopha.2019.108793","volume":"114","author":"Z Hong","year":"2019","unstructured":"Hong Z, Wu G, Xiang ZD, Xu CD, Huang SS, Li C, Shi L, Wu DL. KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN. Biomed Pharmacother. 2019;114:108793.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"4628_CR38","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1093\/nar\/gkz108","volume":"47","author":"Z Shang","year":"2019","unstructured":"Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B, Dong Q, Jiang N, Flores-Morales A, Chang C, et al. LncRNA PCAT1 activates AKT and NF-kappaB signaling in castration-resistant prostate cancer by regulating the PHLPP\/FKBP51\/IKKalpha complex. Nucleic Acids Res. 2019;47(8):4211\u201325.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4628_CR39","first-page":"2340","volume":"18","author":"G Yang","year":"2019","unstructured":"Yang G, Zhou D, Li J, Wang W, Zhong W, Fan W, Yu M, Cheng H. VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer. Oncol Lett. 2019;18(3):2340\u20137.","journal-title":"Oncol Lett"},{"issue":"6","key":"4628_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1248\/cpb.c16-00225","volume":"64","author":"T Noguchi-Yachide","year":"2016","unstructured":"Noguchi-Yachide T. BET bromodomain as a target of epigenetic therapy. Chem Pharm Bull (Tokyo). 2016;64(6):540\u20137.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"7570","key":"4628_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, et al. Transcriptional plasticity promotes primary and acquired resistance to BET Inhibition. Nature. 2015;525(7570):543\u20137.","journal-title":"Nature"},{"issue":"7586","key":"4628_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413\u20137.","journal-title":"Nature"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04628-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:02:33Z","timestamp":1773403353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04628-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4628"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04628-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethic committee of Tongji Hospital, School of Medicine, Tongji University (SBKT-2024-103). The process of clinical sample acquirement confirmed with the ethical requirements. The study also conformed to the provisions of the Declaration of Helsinki. The animal experiments were approved by the Ethics Committee of Tongji Hospital, Tongji University (2024-DW-SB-055). The mice were handled and euthanized according to ethical guideline. This animal experiment was performed in accordance with China General Requirements for Animal Experiment guidelines. We confirmed the tumor the final tumor volume must not exceed 2000 mm\u00b3, and the final tumor weight not exceed 1\/10 (2 g) of the mice\u2019s body weight. Each participate knew the study purpose and volunteered to join and signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publish this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}